She is a statistical analysis of patient data, comparing the rates of comorbidities among individuals with PsA and PsO. Her findings reveal that a significantly higher percentage of patients with PsA (73. 7%) reported comorbidities compared to those with PsO (57. 3%). Her research also indicates that certain medications, including methotrexate, leflunomide, glucocorticoids, and tumor necrosis factor inhibitors, “were more commonly prescribed to patients with PsA.”.. suggesting a potential link between the treatment options and the presence of comorbidities in this population.
Source: Found here
Percentages of overall reported comorbidities were higher among patients with PsA vs PsO (73.7% vs 57.3%; P <.038). Methotrexate ( P <.001), leflunomide ( P =.001), glucocorticoids ( P =.01), and tumor necrosis factor inhibitors ( P =.008) were more commonly used among patients with PsA vs PsO.
